Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its... see more

Recent & Breaking News (NDAQ:IMNM)

Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald

Business Wire December 7, 2021

Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant

Business Wire December 1, 2021

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Business Wire November 29, 2021

Immunome Reports Third Quarter 2021 Financial Results

Business Wire November 15, 2021

Immunome to Present at the Stifel Healthcare Conference

Business Wire November 9, 2021

Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

Business Wire October 20, 2021

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Business Wire October 7, 2021

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Business Wire September 30, 2021

Immunome to Present at the Cantor Global Healthcare Conference

Business Wire September 22, 2021

Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Business Wire September 15, 2021

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

Business Wire September 7, 2021

Immunome Reports Second Quarter 2021 Financial Results

Business Wire August 19, 2021

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Business Wire July 20, 2021

Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Business Wire July 6, 2021

Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

Business Wire June 30, 2021

Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors

Business Wire June 17, 2021

Immunome to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

Business Wire May 20, 2021

Immunome Reports First Quarter 2021 Financial Results

Business Wire May 12, 2021

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Business Wire April 26, 2021